FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:974-975 March 2, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Després, J.-P. PubMed Citation

To the Editor: Després et al. (Nov. 17 issue)¹ report that in the placebo-controlled Rimonabant in Obesity–Lipids (RIO-Lipids) study, rimonabant reduced weight by 5.4 kg in healthy overweight or obese patients with dyslipidemia. This study involved the randomized assignment of only those subjects who were at least 80 percent adherent to a regimen of diet and placebo during a one-month run-in period, yet 40 percent of the patients did not complete the 12-month trial. Small but statistically significant improvements in high-density lipoprotein cholesterol levels, triglyceride levels, and blood pressure were noted. On the basis of these and similar results from . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.